AleAnna (NASDAQ:ANNA – Get Free Report) and Lexeo Therapeutics (NASDAQ:LXEO – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.
Profitability
This table compares AleAnna and Lexeo Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| AleAnna | -46.01% | -14.90% | -8.74% |
| Lexeo Therapeutics | N/A | -86.38% | -67.30% |
Analyst Ratings
This is a breakdown of current recommendations and price targets for AleAnna and Lexeo Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| AleAnna | 1 | 0 | 0 | 0 | 1.00 |
| Lexeo Therapeutics | 1 | 0 | 7 | 1 | 2.89 |
Valuation and Earnings
This table compares AleAnna and Lexeo Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| AleAnna | $25.04 million | 16.91 | -$12.34 million | $0.04 | 158.75 |
| Lexeo Therapeutics | N/A | N/A | -$98.33 million | ($2.19) | -2.92 |
AleAnna has higher revenue and earnings than Lexeo Therapeutics. Lexeo Therapeutics is trading at a lower price-to-earnings ratio than AleAnna, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
38.1% of AleAnna shares are held by institutional investors. Comparatively, 60.7% of Lexeo Therapeutics shares are held by institutional investors. 42.9% of AleAnna shares are held by insiders. Comparatively, 5.3% of Lexeo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Volatility & Risk
AleAnna has a beta of -1.19, suggesting that its share price is 219% less volatile than the S&P 500. Comparatively, Lexeo Therapeutics has a beta of 1.99, suggesting that its share price is 99% more volatile than the S&P 500.
About AleAnna
AleAnna, Inc. engages in oil and gas exploration and production activities. It focuses on Italy’s natural gas reserves and developing renewable energy solutions. The company was founded in 2007 and is headquartered in Dallas, TX.
About Lexeo Therapeutics
Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
Receive News & Ratings for AleAnna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AleAnna and related companies with MarketBeat.com's FREE daily email newsletter.
